Clinical Trial Update: Efficacy and Safety of Tozorakimab in Symptomatic Chronic Obstructive Pulmonary Disease With a History of Exacerbations [Phase 3]

View source ↗

Summary

Phase 3 trial update on Tozorakimab for symptomatic COPD with a history of exacerbations, reporting efficacy and safety results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Obstructive Pulmonary Disease

Drugs mentioned

• Tozorakimab (tozorakimab)

Snippet

Sponsor: AstraZeneca | Conditions: Chronic Obstructive Pulmonary Disease (COPD) | Phase 3 | Status: COMPLETED